The horizon of antiangiogenic therapy for colorectal cancer

Keyphrases

• Colorectal Cancer 100%
• Bevacizumab 100%
• Antiangiogenic Therapy 100%
• Patient Survival 50%
• U.S. Food 50%
• Vascular Endothelial Growth Factor 50%
• Progression-free Survival 50%
• Ongoing Trials 50%
• Commercially Available 50%
• Metastatic Spread 50%
• Metastatic Colorectal Cancer (mCRC) 50%
• Fluorouracil 50%
• Bevacizumab Therapy 50%
• Avastin 50%
• Angiogenesis Inhibitors 50%
• Fluoropyrimidine-based Chemotherapy 50%
• Additional Indications 50%
• Vascular Endothelial Growth Factor Inhibitors 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Bevacizumab 100%
• Colorectal Carcinoma 100%
• Antiangiogenic Therapy 100%
• Malignant Neoplasm 25%
• Side Effect 25%
• Chemotherapy 25%
• Progression Free Survival 25%
• Vasculotropin 25%
• Fluorouracil 25%
• Angiogenesis Inhibitor 25%
• Metastatic Colorectal Cancer 25%
• Vasculotropin Inhibitor 25%